Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL.
Publication/Presentation Date
2-1-2020
Abstract
Cytotoxic T-lymphocyte antigen 4 (CTLA4)-FasL, a homo-hexameric signal converter protein, is capable of inducing robust apoptosis in malignant cells of the B-cell lineage expressing its cognate B7 and Fas targets, while sparing nonmalignant ones. This fusion protein's striking proapoptotic efficacy stems from its complementary abilities to coordinately activate apoptotic signals and abrogate antiapoptotic ones. A limiting factor in translating FasL or Fas receptor agonists into the clinic has been lethal hepatotoxicity. Here, we establish CTLA4-FasL's
Volume
19
Issue
2
First Page
513
Last Page
524
ISSN
1538-8514
Published In/Presented At
Makdasi, E., Amsili, S., Aronin, A., Prigozhina, T. B., Tzdaka, K., Gozlan, Y. M., Ben Gigi-Tamir, L., Sagiv, J. Y., Shkedy, F., Shani, N., Tykocinski, M. L., & Dranitzki Elhalel, M. (2020). Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL. Molecular cancer therapeutics, 19(2), 513–524. https://doi.org/10.1158/1535-7163.MCT-19-0558
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
31871267
Department(s)
Administration and Leadership
Document Type
Article